urea has been researched along with Allodynia in 25 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain." | 5.33 | Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. ( Bayburt, EK; Didomenico, S; Drizin, I; Faltynek, CR; Gomtsyan, A; Hannick, SM; Honore, P; Jarvis, MF; Jinkerson, T; Koenig, JR; Lee, CH; Macri, BS; Marsh, KC; McDonald, HA; Oie, T; Perner, RJ; Schmidt, RG; Stewart, KD; Surowy, CS; Turner, S; Wetter, J; Wismer, CT; Zheng, GZ, 2005) |
| " Furthermore, A-425619 maintained efficacy in the postoperative pain model after twice daily dosing p." | 5.33 | A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. ( El Kouhen, R; Faltynek, CR; Gauvin, DM; Gomtsyan, A; Honore, P; Jarvis, MF; Lee, CH; Marsh, K; Mikusa, J; Sullivan, JP; Wismer, CT; Zhong, C; Zhu, CZ, 2005) |
| " Previously, we demonstrated that DAGLβ inactivation using the triazole urea inhibitor KT109 blocked macrophage inflammatory signaling and reversed allodynic responses of mice in inflammatory and neuropathic pain models." | 3.88 | Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. ( Donvito, G; Fox, TE; Hsu, KL; Kester, M; Lichtman, AH; Schurman, LD; Shin, M; Snyder, HW, 2018) |
| "Oxaliplatin-induced cold allodynia was alleviated by the TRPM8 blockers N-(2-aminoethyl)-N-[4-(benzyloxy)-3-methoxybenzyl]-N'-(1S)-1-(phenyl) ethyl] urea and TC-I 2014." | 3.83 | Involvement of c-Myc-mediated transient receptor potential melastatin 8 expression in oxaliplatin-induced cold allodynia in mice. ( Andoh, T; Kuraishi, Y; Mizoguchi, S; Yakura, T, 2016) |
| " In all models, URB937 was as effective or more effective than standard analgesic and anti-inflammatory drugs (indomethacin, gabapentin, dexamethasone) and reversed pain-related responses (mechanical hyperalgesia, thermal hyperalgesia, and mechanical allodynia) in a dose-dependent manner." | 3.78 | Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. ( Armirotti, A; Bandiera, T; Bertorelli, R; Colombano, G; Moreno-Sanz, G; Piomelli, D; Reggiani, A; Sasso, O; Scarpelli, R, 2012) |
| "Vanilloid receptor type 1 (TRPV1) is a ligand-gated nonselective cation channel that is considered to be an important integrator of various pain stimuli such as endogenous lipids, capsaicin, heat, and low pH." | 3.73 | TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. ( Bayburt, EK; Bianchi, B; Brown, B; Chandran, P; Cui, M; Decker, MW; Faltynek, CR; Gauvin, D; Gomtsyan, A; Hernandez, G; Honore, P; Lee, CH; Marsh, K; McDonald, H; Mikusa, J; Moreland, RB; Neelands, TR; Niforatos, W; Sullivan, JP; Zhong, C, 2006) |
| " SB-705498 is a potent, selective and orally bioavailable TRPV1 antagonist with demonstrated efficacy in a number of preclinical pain models." | 2.73 | The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. ( Appleby, JM; Aylott, MC; Brooke, AC; Bullman, JN; Chizh, BA; Gray, EJ; Lai, RY; Napolitano, A; O'Donnell, MB; Wang, J; Williams, PM, 2007) |
| "Mechanical allodynia and thermal hyperalgesia were evaluated using von Frey filaments and a thermal stimulus." | 1.56 | Chemical stimulation of the lateral hypothalamus induces antiallodynic and anti-thermal hyperalgesic effects in animal model of neuropathic pain: Involvement of orexin receptors in the spinal cord. ( Haghparast, A; Kashfi, K; Manaheji, H; Salehi, S, 2020) |
| "Meanwhile, thermal hyperalgesia was observed from day 2 through day 10 and mechanical allodynia from day 4 through day 10." | 1.40 | Glycogen synthase kinase 3 beta regulates glial glutamate transporter protein expression in the spinal dorsal horn in rats with neuropathic pain. ( Gao, M; Maixner, DW; Weng, HR, 2014) |
| "Pain is the leading cause of emergency department visits, hospitalizations, and daily suffering in individuals with sickle cell disease (SCD)." | 1.37 | Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. ( Barabas, ME; Brandow, AM; Hillery, CA; Kerstein, PC; Retherford, D; Stucky, CL; Vilceanu, D; Wandersee, NJ, 2011) |
| "Assessment of RTX hyperalgesia by measurement of the paw withdrawal latency with a plantar test apparatus yielded 30 mg/kg minimum effective dose for each antagonist." | 1.36 | Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath. ( Bölcskei, K; Dézsi, L; Horváth, C; Kis-Varga, A; Petho, G; Szentirmay, E; Szolcsányi, J; Tékus, V; Visegrády, A, 2010) |
| " The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain." | 1.33 | Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. ( Bayburt, EK; Didomenico, S; Drizin, I; Faltynek, CR; Gomtsyan, A; Hannick, SM; Honore, P; Jarvis, MF; Jinkerson, T; Koenig, JR; Lee, CH; Macri, BS; Marsh, KC; McDonald, HA; Oie, T; Perner, RJ; Schmidt, RG; Stewart, KD; Surowy, CS; Turner, S; Wetter, J; Wismer, CT; Zheng, GZ, 2005) |
| " Furthermore, A-425619 maintained efficacy in the postoperative pain model after twice daily dosing p." | 1.33 | A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. ( El Kouhen, R; Faltynek, CR; Gauvin, DM; Gomtsyan, A; Honore, P; Jarvis, MF; Lee, CH; Marsh, K; Mikusa, J; Sullivan, JP; Wismer, CT; Zhong, C; Zhu, CZ, 2005) |
| "Because NMDA activity mediates hyperalgesia, we tested the hypothesis that PAR-1 receptors also regulate pain processing." | 1.32 | Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin. ( Fang, M; Fisher, LL; Kovács, KJ; Larson, AA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, WJ | 1 |
| Wang, YY | 1 |
| Zhao, Y | 1 |
| Jia, H | 1 |
| Tang, JS | 1 |
| Huo, FQ | 1 |
| Liu, H | 1 |
| Salehi, S | 1 |
| Kashfi, K | 1 |
| Manaheji, H | 1 |
| Haghparast, A | 1 |
| Matsuura, W | 1 |
| Nakamoto, K | 1 |
| Tokuyama, S | 1 |
| Cagli, A | 1 |
| Senol, SP | 1 |
| Temiz-Resitoglu, M | 1 |
| Guden, DS | 1 |
| Sari, AN | 1 |
| Sahan-Firat, S | 1 |
| Tunctan, B | 1 |
| Shin, M | 1 |
| Snyder, HW | 1 |
| Donvito, G | 1 |
| Schurman, LD | 1 |
| Fox, TE | 1 |
| Lichtman, AH | 1 |
| Kester, M | 1 |
| Hsu, KL | 1 |
| Araldi, D | 1 |
| Ferrari, LF | 1 |
| Levine, JD | 1 |
| Weng, HR | 1 |
| Gao, M | 1 |
| Maixner, DW | 1 |
| Wardach, J | 1 |
| Wagner, M | 1 |
| Jeong, Y | 1 |
| Holden, JE | 1 |
| Mizoguchi, S | 1 |
| Andoh, T | 1 |
| Yakura, T | 1 |
| Kuraishi, Y | 1 |
| Tékus, V | 1 |
| Bölcskei, K | 1 |
| Kis-Varga, A | 1 |
| Dézsi, L | 1 |
| Szentirmay, E | 1 |
| Visegrády, A | 1 |
| Horváth, C | 1 |
| Szolcsányi, J | 1 |
| Petho, G | 1 |
| Adedoyin, MO | 1 |
| Vicini, S | 1 |
| Neale, JH | 1 |
| Hillery, CA | 1 |
| Kerstein, PC | 1 |
| Vilceanu, D | 1 |
| Barabas, ME | 1 |
| Retherford, D | 1 |
| Brandow, AM | 1 |
| Wandersee, NJ | 1 |
| Stucky, CL | 1 |
| Sasso, O | 1 |
| Bertorelli, R | 1 |
| Bandiera, T | 1 |
| Scarpelli, R | 1 |
| Colombano, G | 1 |
| Armirotti, A | 1 |
| Moreno-Sanz, G | 1 |
| Reggiani, A | 1 |
| Piomelli, D | 1 |
| Mazzardo-Martins, L | 1 |
| Martins, DF | 1 |
| Stramosk, J | 1 |
| Cidral-Filho, FJ | 1 |
| Santos, AR | 1 |
| Fang, M | 1 |
| Kovács, KJ | 1 |
| Fisher, LL | 1 |
| Larson, AA | 1 |
| Gomtsyan, A | 3 |
| Bayburt, EK | 2 |
| Schmidt, RG | 1 |
| Zheng, GZ | 1 |
| Perner, RJ | 1 |
| Didomenico, S | 1 |
| Koenig, JR | 1 |
| Turner, S | 1 |
| Jinkerson, T | 1 |
| Drizin, I | 1 |
| Hannick, SM | 1 |
| Macri, BS | 1 |
| McDonald, HA | 1 |
| Honore, P | 3 |
| Wismer, CT | 2 |
| Marsh, KC | 1 |
| Wetter, J | 1 |
| Stewart, KD | 1 |
| Oie, T | 1 |
| Jarvis, MF | 3 |
| Surowy, CS | 1 |
| Faltynek, CR | 4 |
| Lee, CH | 3 |
| Mikusa, J | 2 |
| Zhu, CZ | 1 |
| Zhong, C | 2 |
| Gauvin, DM | 1 |
| El Kouhen, R | 1 |
| Marsh, K | 2 |
| Sullivan, JP | 2 |
| Kajiyama, S | 1 |
| Kawamoto, M | 1 |
| Shiraishi, S | 1 |
| Gaus, S | 1 |
| Matsunaga, A | 1 |
| Suyama, H | 1 |
| Yuge, O | 1 |
| McGaraughty, S | 1 |
| Chu, KL | 1 |
| Cui, M | 1 |
| Gauvin, D | 1 |
| Hernandez, G | 1 |
| Chandran, P | 1 |
| Brown, B | 1 |
| Bianchi, B | 1 |
| McDonald, H | 1 |
| Niforatos, W | 1 |
| Neelands, TR | 1 |
| Moreland, RB | 1 |
| Decker, MW | 1 |
| Chizh, BA | 1 |
| O'Donnell, MB | 1 |
| Napolitano, A | 1 |
| Wang, J | 1 |
| Brooke, AC | 1 |
| Aylott, MC | 1 |
| Bullman, JN | 1 |
| Gray, EJ | 1 |
| Lai, RY | 1 |
| Williams, PM | 1 |
| Appleby, JM | 1 |
| Roberts, LA | 1 |
| Connor, M | 1 |
| Urban, L | 1 |
| Campbell, EA | 1 |
| Panesar, M | 1 |
| Patel, S | 1 |
| Chaudhry, N | 1 |
| Kane, S | 1 |
| Buchheit, KH | 1 |
| Sandells, B | 1 |
| James, IF | 2 |
| Jaggar, SI | 1 |
| Scott, HC | 1 |
| Rice, AS | 1 |
| Bingham, S | 1 |
| Davey, PT | 1 |
| Babbs, AJ | 1 |
| Irving, EA | 1 |
| Sammons, MJ | 1 |
| Wyles, M | 1 |
| Jeffrey, P | 1 |
| Cutler, L | 1 |
| Riba, I | 1 |
| Johns, A | 1 |
| Porter, RA | 1 |
| Upton, N | 1 |
| Hunter, AJ | 1 |
| Parsons, AA | 1 |
1 review available for urea and Allodynia
| Article | Year |
|---|---|
TRPV1 antagonists as a potential treatment for hyperalgesia.
Topics: Analgesics; Animals; Humans; Hyperalgesia; Structure-Activity Relationship; TRPV Cation Channels; Ur | 2006 |
1 trial available for urea and Allodynia
| Article | Year |
|---|---|
The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Cohort Studies; Dose-Response Relationship, Dru | 2007 |
23 other studies available for urea and Allodynia
| Article | Year |
|---|---|
Involvement of 5-HT2A, 5-HT2B and 5-HT2C receptors in mediating the ventrolateral orbital cortex-induced antiallodynia in a rat model of neuropathic pain.
Topics: Animals; Hyperalgesia; Indoles; Male; Neuralgia; Prefrontal Cortex; Rats, Sprague-Dawley; Receptor, | 2020 |
Chemical stimulation of the lateral hypothalamus induces antiallodynic and anti-thermal hyperalgesic effects in animal model of neuropathic pain: Involvement of orexin receptors in the spinal cord.
Topics: Animals; Benzoxazoles; Carbachol; Disease Models, Animal; Dose-Response Relationship, Drug; Hot Temp | 2020 |
Involvement of descending pain control system regulated by orexin receptor signaling in the induction of central post-stroke pain in mice.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Benzoxazoles; Brain; Brain Ischemia; Hyperalgesia; | 2020 |
Soluble epoxide hydrolase inhibitor trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea prevents hyperalgesia through regulating NLRC4 inflammasome-related pro-inflammatory and anti-inflammatory signaling pathways in the lipopolysaccharide-induced pa
Topics: Animals; Anti-Inflammatory Agents; Epoxide Hydrolases; Hyperalgesia; Inflammasomes; Intercellular Si | 2021 |
Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Disease Models, Animal; Enzyme Inhibitors; Huma | 2018 |
Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat.
Topics: Analgesics, Opioid; Animals; Dinoprostone; Dose-Response Relationship, Drug; Hyperalgesia; Injection | 2018 |
Glycogen synthase kinase 3 beta regulates glial glutamate transporter protein expression in the spinal dorsal horn in rats with neuropathic pain.
Topics: Amino Acid Transport System X-AG; Animals; Astrocytes; Disease Models, Animal; Drug Administration R | 2014 |
Lateral Hypothalamic Stimulation Reduces Hyperalgesia Through Spinally Descending Orexin-A Neurons in Neuropathic Pain.
Topics: Analgesics, Non-Narcotic; Animals; Benzoxazoles; Carbachol; Female; Hyperalgesia; Hypothalamic Area, | 2016 |
Involvement of c-Myc-mediated transient receptor potential melastatin 8 expression in oxaliplatin-induced cold allodynia in mice.
Topics: Animals; Benzyl Compounds; Ganglia, Spinal; Hyperalgesia; Male; Mice; Organoplatinum Compounds; Oxal | 2016 |
Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath.
Topics: Acrylamides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cold Temperature; Disease Models, Ani | 2010 |
Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model.
Topics: Amygdala; Animals; Behavior, Animal; Dipeptides; Disease Models, Animal; Excitatory Postsynaptic Pot | 2010 |
Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease.
Topics: Action Potentials; Anemia, Sickle Cell; Animals; Capsaicin; Disease Models, Animal; Female; Humans; | 2011 |
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
Topics: Amidohydrolases; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experiment | 2012 |
Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: evidence for the mechanisms of action.
Topics: Analgesics; Animals; Arginine; Cytokines; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Hyperalgesi | 2012 |
Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin.
Topics: Acetic Acid; Amino Acid Chloromethyl Ketones; Animals; Behavior, Animal; Capillary Permeability; End | 2003 |
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
Topics: Abdominal Pain; Administration, Oral; Analgesics; Animals; Biological Availability; Calcium; Cells, | 2005 |
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
Topics: Acute Disease; Analgesics; Animals; Capsaicin; Carrageenan; Chronic Disease; Dose-Response Relations | 2005 |
Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats.
Topics: Animals; Behavior, Animal; Benzoxazoles; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dos | 2005 |
Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats.
Topics: Action Potentials; Animals; Evoked Potentials, Somatosensory; Freund's Adjuvant; Ganglia, Spinal; Hy | 2006 |
TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
Topics: Administration, Oral; Analgesics; Animals; Arthralgia; Calcium; Capsaicin; Cell Line; Cells, Culture | 2006 |
In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue.
Topics: Analgesics; Animals; Behavior, Animal; Blinking; Blood Pressure; Bronchoconstriction; Capsaicin; Car | 2000 |
The capsaicin analogue SDZ249-665 attenuates the hyper-reflexia and referred hyperalgesia associated with inflammation of the rat urinary bladder.
Topics: Algorithms; Analgesics; Animals; Capsaicin; Cystitis; Dose-Response Relationship, Drug; Hyperalgesia | 2001 |
Orexin-A, an hypothalamic peptide with analgesic properties.
Topics: Abdomen; Analgesics; Anesthesia, Intravenous; Animals; Behavior, Animal; Benzoxazoles; Carrageenan; | 2001 |